Comparative survival of Asian and white metastatic castration-resistant prostate cancer men treated with docetaxel

Susan Halabi; Sandipan Dutta; Catherine M. Tangen; Mark Rosenthal; Daniel P. Petrylak; Ian M. Thompson; Kim N. Chi; Johann S. de Bono; John C. Araujo; Christopher Logothetis; Mario A. Eisenberger; David I. Quinn; Karim Fizazi; Michael J. Morris; Celestia S. Higano; Ian F. Tannock; Eric J. Small; William Kevin Kelly

doi:10.1093/JNCICS/PKAA003

Comparative survival of Asian and white metastatic castration-resistant prostate cancer men treated with docetaxel

Susan Halabi, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson, Kim N. Chi, Johann S. de Bono, John C. Araujo, Christopher Logothetis, Mario A. Eisenberger, David I. Quinn, Karim Fizazi, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small, William Kevin Kelly

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

3 Citations (Scopus)

Résumé

There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] ¼ 17.4 to 22.1 months) and 21.2 months (95% CI ¼ 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI ¼ 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel.

langue originale	Anglais
Numéro d'article	PKAA003
journal	JNCI Cancer Spectrum
Volume	4
Numéro de publication	2
Les DOIs	https://doi.org/10.1093/JNCICS/PKAA003
état	Publié - 1 janv. 2020

Accès au document

10.1093/JNCICS/PKAA003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Halabi, S., Dutta, S., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Thompson, I. M., Chi, K. N., de Bono, J. S., Araujo, J. C., Logothetis, C., Eisenberger, M. A., Quinn, D. I., Fizazi, K., Morris, M. J., Higano, C. S., Tannock, I. F., Small, E. J., & Kelly, W. K. (2020). Comparative survival of Asian and white metastatic castration-resistant prostate cancer men treated with docetaxel. JNCI Cancer Spectrum, 4(2), Article PKAA003. https://doi.org/10.1093/JNCICS/PKAA003

@article{5eb080dba7814fddb20ecf5e5c3581b9,

title = "Comparative survival of Asian and white metastatic castration-resistant prostate cancer men treated with docetaxel",

abstract = "There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] ¼ 17.4 to 22.1 months) and 21.2 months (95% CI ¼ 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI ¼ 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel.",

author = "Susan Halabi and Sandipan Dutta and Tangen, {Catherine M.} and Mark Rosenthal and Petrylak, {Daniel P.} and Thompson, {Ian M.} and Chi, {Kim N.} and {de Bono}, {Johann S.} and Araujo, {John C.} and Christopher Logothetis and Eisenberger, {Mario A.} and Quinn, {David I.} and Karim Fizazi and Morris, {Michael J.} and Higano, {Celestia S.} and Tannock, {Ian F.} and Small, {Eric J.} and Kelly, {William Kevin}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2020",

month = jan,

day = "1",

doi = "10.1093/JNCICS/PKAA003",

language = "English",

volume = "4",

journal = "JNCI Cancer Spectrum",

issn = "2515-5091",

number = "2",

}

Halabi, S, Dutta, S, Tangen, CM, Rosenthal, M, Petrylak, DP, Thompson, IM, Chi, KN, de Bono, JS, Araujo, JC, Logothetis, C, Eisenberger, MA, Quinn, DI, Fizazi, K, Morris, MJ, Higano, CS, Tannock, IF, Small, EJ & Kelly, WK 2020, 'Comparative survival of Asian and white metastatic castration-resistant prostate cancer men treated with docetaxel', JNCI Cancer Spectrum, VOL. 4, Numéro 2, PKAA003. https://doi.org/10.1093/JNCICS/PKAA003

TY - JOUR

T1 - Comparative survival of Asian and white metastatic castration-resistant prostate cancer men treated with docetaxel

AU - Halabi, Susan

AU - Dutta, Sandipan

AU - Tangen, Catherine M.

AU - Rosenthal, Mark

AU - Petrylak, Daniel P.

AU - Thompson, Ian M.

AU - Chi, Kim N.

AU - de Bono, Johann S.

AU - Araujo, John C.

AU - Logothetis, Christopher

AU - Eisenberger, Mario A.

AU - Quinn, David I.

AU - Fizazi, Karim

AU - Morris, Michael J.

AU - Higano, Celestia S.

AU - Tannock, Ian F.

AU - Small, Eric J.

AU - Kelly, William Kevin

PY - 2020/1/1

Y1 - 2020/1/1

N2 - There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] ¼ 17.4 to 22.1 months) and 21.2 months (95% CI ¼ 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI ¼ 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel.

AB - There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] ¼ 17.4 to 22.1 months) and 21.2 months (95% CI ¼ 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI ¼ 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel.

UR - http://www.scopus.com/inward/record.url?scp=85085743963&partnerID=8YFLogxK

U2 - 10.1093/JNCICS/PKAA003

DO - 10.1093/JNCICS/PKAA003

M3 - Article

AN - SCOPUS:85085743963

SN - 2515-5091

VL - 4

JO - JNCI Cancer Spectrum

JF - JNCI Cancer Spectrum

IS - 2

M1 - PKAA003

ER -